Regulatory Roadblock: FDA Places Clinical Hold on REGENXBIO’s RGX-121 Gene Therapy for Hunter Syndrome Following Asymptomatic Spine Findings
Executive Overview In a significant regulatory setback for the biotechnology sector, the United States Food and Drug Administration (FDA) has...
